Justin Eyquem

Title: Justin Eyquem: Innovator in Chimeric Antigen Receptors

Introduction

Justin Eyquem is a prominent inventor based in Paris, France. He is known for his groundbreaking work in the field of immunotherapy, particularly in the development of chimeric antigen receptors (CARs). His innovative approach aims to enhance the specificity and reactivity of immune cells against targeted threats, such as cancer and viral infections.

Latest Patents

Justin Eyquem holds a patent for a "Multi-chain chimeric antigen receptor and uses thereof." This invention introduces a new generation of CARs, referred to as multi-chain CARs. These CARs are designed to redirect immune cell specificity by utilizing separate extracellular ligand binding and signaling domains in different transmembrane polypeptides. The architecture of these CARs is closer to natural receptors, which optimizes signal transduction. The invention includes polynucleotides, vectors encoding the multi-chain CAR, and isolated cells expressing them, particularly for their application in immunotherapy.

Career Highlights

Justin Eyquem is associated with Cellectis, a company that focuses on developing innovative immunotherapies. His work has significantly contributed to the advancement of adoptive immunotherapy strategies, paving the way for more effective treatments for cancer and viral infections.

Collaborations

Some of Justin Eyquem's notable coworkers include Julianne Smith and Andrew M Scharenberg. Their collaborative efforts in research and development have further enhanced the potential of CAR technology in therapeutic applications.

Conclusion

Justin Eyquem's contributions to the field of immunotherapy through his innovative patent on multi-chain chimeric antigen receptors mark a significant advancement in cancer treatment strategies. His work continues to inspire further research and development in this critical area of medicine.